Alevroudis, E.; Spei, M.-E.; Chatziioannou, S.N.; Tsoli, M.; Wallin, G.; Kaltsas, G.; Daskalakis, K.
Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers 2021, 13, 1813.
https://doi.org/10.3390/cancers13081813
AMA Style
Alevroudis E, Spei M-E, Chatziioannou SN, Tsoli M, Wallin G, Kaltsas G, Daskalakis K.
Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers. 2021; 13(8):1813.
https://doi.org/10.3390/cancers13081813
Chicago/Turabian Style
Alevroudis, Emmanouil, Maria-Eleni Spei, Sofia N. Chatziioannou, Marina Tsoli, Göran Wallin, Gregory Kaltsas, and Kosmas Daskalakis.
2021. "Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis" Cancers 13, no. 8: 1813.
https://doi.org/10.3390/cancers13081813
APA Style
Alevroudis, E., Spei, M. -E., Chatziioannou, S. N., Tsoli, M., Wallin, G., Kaltsas, G., & Daskalakis, K.
(2021). Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. Cancers, 13(8), 1813.
https://doi.org/10.3390/cancers13081813